Nathaniel C. Swinburne

Nathaniel C. Swinburne

Auto-generated profile, based on publicly available information

Nathaniel C. Swinburne

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JTJoseph J. Titano
Joseph J. Titano
MBMarcus Badgeley
Marcus Badgeley
JSJavin Schefflein
Javin Schefflein
MPMargaret Pain
Margaret Pain
ASAndres Su
Andres Su
EOEric K. Oermann
Eric K. Oermann

1 June 2015 in Techniques in Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AFAaron Fischman
Aaron Fischman
NSNathaniel C. Swinburne
Nathaniel C. Swinburne
RPRahul S. Patel
Rahul S. Patel

1 June 2019 in Annals of Translational Medicine
Verified
Journal Article
Closed access
PDF file
NSNathaniel C. Swinburne
Nathaniel C. Swinburne
JSJavin Schefflein
Javin Schefflein
YSYu Sakai
Yu Sakai
EOEric Karl Oermann
Eric Karl Oermann
JTJoseph J. Titano
Joseph J. Titano
KNKambiz Nael
Kambiz Nael
Background: Differentiating glioblastoma, brain metastasis, and central nervous system lymphoma (CNSL) on conventional magnetic resonance imaging (MRI) can present a diagnostic dilemma due to the potential for overlapping imaging features. We investigate whether machine learning evaluation of multimodal MRI can reliably differentiate these entities. Methods: Preoperative brain MRI including diffusion weighted imaging (DWI), dynamic contrast enhanced (DCE), and dynamic susceptibility contrast (DSC) perfusion in patients with glioblastoma, lymphoma, or metastasis were retrospectively reviewed. Perfusion maps (rCBV, rCBF), permeability maps (K-trans, Kep, Vp, Ve), ADC, T1C+ and T2/FLAIR images were coregistered and two separate volumes of interest (VOIs) were obtained from the enhancing tumor and non-enhancing T2 hyperintense (NET2) regions. The tumor volumes obtained from these VOIs were utilized for supervised training of support vector classifier (SVC) and multilayer perceptron (MLP) models. Validation of the trained models was performed on unlabeled cases using the leave-one-subject-out method. Head-to-head and multiclass models were created. Accuracies of the multiclass models were compared against two human interpreters reviewing conventional and diffusion-weighted MR images. Results: Twenty-six patients enrolled with histopathologically-proven glioblastoma (n=9), metastasis (n=9), and CNS lymphoma (n=8) were included. The trained multiclass ML models discriminated the three pathologic classes with a maximum accuracy of 69.2% accuracy (18 out of 26; kappa 0.540, P=0.01) using an MLP trained with the VpNET2 tumor volumes. Human readers achieved 65.4% (17 out of 26) and 80.8% (21 out of 26) accuracies, respectively. Using the MLP VpNET2 model as a computer-aided diagnosis (CADx) for cases in which the human reviewers disagreed with each other on the diagnosis resulted in correct diagnoses in 5 (19.2%) additional cases. Conclusions: Our trained multiclass MLP using VpNET2 can differentiate glioblastoma, brain metastasis, and CNS lymphoma with modest diagnostic accuracy and provides approximately 19% increase in diagnostic yield when added to routine human interpretation.

1 January 2021 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
JSJoseph N. Stember
Joseph N. Stember
HCHaydar Celik
Haydar Celik
DGDavid Gutman
David Gutman
NSNathaniel Swinburne
Nathaniel Swinburne
RYRobert Young
Robert Young
UBUlas Bagci
Ulas Bagci
A deep learning (DL) model trained with eye-tracking data combined with speech-recognition data can automatically extract labeled data from clinical interpretations for DL, producing a large volume... Purpose To generate and assess an algorithm combining eye tracking and speech recognition to extract brain lesion location labels automatically for deep learning (DL). Materials and Methods In this...

2 May 2017 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
NSNathaniel C. Swinburne
Nathaniel C. Swinburne
ABAnmol G. Bansal
Anmol G. Bansal
AAAmit Aggarwal
Amit Aggarwal
ADAmish H. Doshi
Amish H. Doshi

1 June 2017 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
NSNathaniel C. Swinburne
Nathaniel C. Swinburne
DBDerek M. Biederman
Derek M. Biederman
CBCecilia Besa
Cecilia Besa
NTNora E. Tabori
Nora E. Tabori
AFAaron M. Fischman
Aaron M. Fischman
EKEdward Kim
Edward Kim
The optimal palliative treatment for unresectable intrahepatic cholangiocarcinoma (ICC) remains controversial. While selective internal radiation therapy (SIRT) using yttrium-90 microspheres is a well-accepted treatment for hepatocellular carcinoma, data related to its use for locally advanced ICC remain relatively scarce. Twenty-nine patients (mean age 66 ± 11 years; 15 female) with unresectable biopsy-proven ICC treated with SIRT between June 2008 and April 2015 were retrospectively evaluated for post-treatment toxicity, overall survival, and imaging response using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. RECIST 1.1 response was evaluable following 26 treatments [complete response (CR):0, partial response (PR):3; stable disease (SD):16, progression of disease (PD):7]. Objective response rate (CR+PR) was 12%. Disease control rate (CR+PR+SD) was 73%. Median time to progression was 5.6 [95% confidence interval (CI): 0–12.0] months. Median survival following SIRT was 9.1 (95% CI: 1.7–16.4) months. Post-treatment survival was prolonged in patients with absence of extrahepatic disease (p = 0.03) and correlated with RECIST 1.1 response (p = 0.02). Toxicities were limited to grade I severity and occurred following 27% of treatments. These findings support the safe, effective use of SIRT for unresectable ICC. Post-treatment survival is prolonged in patients with absence of extrahepatic disease at baseline. RECIST 1.1 response following SIRT for ICC is predictive of survival.